Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Hydroxyurea in Transfusion Dependent β-thalassemia
NCT07292259Phase 2Completed
- Sponsor
- Pakistan Blood and Marrow Transplant Group
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide and hydroxyurea in beta thalassemia, sponsored by Pakistan Blood and Marrow Transplant Group. Primary endpoint: Number of Red Blood Cell Transfusions at 1 year. Started Jan 2024; status: completed.
02
Drugs
thalidomidehydroxyurea
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT07292259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292259.